We are an Australian biopharmaceutical company, focused on drug development platforms and the production of medical grade biopharmaceuticals. We will deliver first-line and adjunct treatments for select autoimmune, gastrointestinal and dermatological conditions.
There is a clear need to develop safe and effective treatments for immune-mediated inflammatory diseases. Our research is directed at improving specific characteristics of select proteins for autoimmune conditions. We are targeting key features of the protein to improve its clinical efficacy and to complement existing drug therapies.
We have isolated and characterised select microbial species and undertaken extensive pre-clinical investigations to develop highly defined medicines, addressing inflammatory and autoimmune conditions.
Human clinical trials will confirm the clinical utility of these medicines, with the aim to advance safe and effective treatments.
At Servatus one of our key projects is the development of pharmaceutical grade live microbial biotherapeutic agents, derived from microorganisms predominantly of bacterial origin.